Skip to main content
Back
Watch Compare

CHINA PHARMA HOLDINGS, INC.

Data quality: 100%
CPHI
NYSE Manufacturing Chemicals
$0.66
▲ $0.04 (5.65%)
Mkt Cap: 3.29 M
Price
$0.66
Mkt Cap
3.29 M
Day Range
$0.53 — $0.66
52-Week Range
$0.50 — $2.60
Volume
13,178
Open $0.53
50D / 200D Avg
$0.70
6.48% below
50D / 200D Avg
$1.40
53.30% below

Quick Summary

Key Takeaways

Revenue declined -19.03% annually over 5 years
Debt/Equity of 0.17 — conservative balance sheet
Generating 88,937.0 in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10.54%
Capital efficient — spends only 1.43% of revenue on capex

Growth

Revenue Growth (5Y)
-19.03%
Below sector avg (1.82%)
Revenue (1Y)-8.49%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-43.15%
Above sector avg (-53.47%)
ROIC-24.94%
Net Margin-76.91%
Op. Margin-78.16%

Safety

Debt / Equity
0.17
Below sector avg (0.31)
Current Ratio0.35
Interest Coverage-118.77

Valuation

PE (TTM)
-1.03
Above sector avg (-1.47)
P/B Ratio0.40
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -1.0 -1.5
P/B 0.4 1.6
ROE % -43.2 -53.5
Net Margin % -76.9 -41.5
Rev Growth 5Y % -19.0 1.8
D/E 0.2 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -8.49% Revenue Growth (3Y) -23.12%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -19.03% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4.14 M Net Income (TTM) -3.19 M
ROE -43.15% ROA -21.56%
Gross Margin -3.18% Operating Margin -78.16%
Net Margin -76.91% Free Cash Flow (TTM) 88,937.0
ROIC -24.94% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.17 Current Ratio 0.35
Interest Coverage -118.77 Asset Turnover 0.28
Working Capital -4.29 M Tangible Book Value -461,039
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.03 Forward P/E N/A
P/B Ratio 0.40 P/S Ratio 0.79
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 2.70%
Market Cap 3.29 M Enterprise Value 4.44 M
Per Share
EPS (Diluted TTM) -0.74 Revenue / Share 0.83
FCF / Share 0.02 OCF / Share 0.03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1.43% FCF Conversion -2.79%
SBC-Adj. FCF N/A Growth Momentum 10.54

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4.14 M 4.53 M 7.01 M 8.10 M 9.64 M
Net Income -3.19 M -4.74 M -3.08 M -3.97 M -3.40 M
EPS (Diluted) -0.74 -0.27 -0.91 -0.76 —
Gross Profit -131,950.0 -1.99 M -281,085.0 -493,916.0 349,270.0
Operating Income -3.24 M -4.59 M -2.75 M -3.55 M -2.86 M
EBITDA — — — — —
R&D Expenses 280,901.0 283,942.0 240,080.0 185,858.0 318,964.0
SG&A Expenses — — — — —
D&A 1.50 M 2.62 M 2.75 M 2.70 M 3.09 M
Interest Expense 27,272.0 27,353.0 333,600.0 434,619.0 542,001.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 31.00 M 14.89 M 16.47 M 17.78 M 22.65 M
Total Liabilities 8.26 M 7.14 M 9.01 M 13.49 M 16.63 M
Shareholders' Equity 22.74 M 7.75 M 7.45 M 4.29 M 6.02 M
Total Debt 1.44 M 1.14 M — — —
Cash & Equivalents 345,112.0 600,000.0 1.42 M 2.03 M 4.86 M
Current Assets 2.35 M 3.27 M 6.00 M 5.96 M 9.09 M
Current Liabilities 7.40 M 5.02 M 6.82 M 12.74 M 10.51 M